Key result
Adrenal nodules linked to ~168% higher odds of dexamethasone nonsuppression during primary aldosteronism evaluation.
Observational (n=883)
In patients evaluated for primary aldosteronism, dexamethasone nonsuppression is associated with the presence of adrenal nodules and worse renal function even in the absence of nodules.
DST nonsuppression may reflect subclinical hypercortisolism in primary aldosteronism; leaves open effects on renal outcomes and management.
BACKGROUND: The 1-mg dexamethasone suppression test (DST) nonsuppression is increasingly recognized beyond adrenal incidentaloma, but its prevalence and clinical significance in patients evaluated for primary aldosteronism (PA) remain unclear, particularly in those without adrenal nodules. METHODS: In this prospective observational study, consecutive patients with hypertension suspected of PA underwent standardized hormonal evaluation, including the 1-mg DST. DST nonsuppression was defined as post-DST serum cortisol >1.8 μg/dL in the absence of overt Cushing's syndrome. Patients were classified as non-PA or confirmed PA and further stratified by adrenal nodules status on computed tomography. Associations with DST nonsuppression were examined using multivariable logistic regression and propensity score-based analyses, with overlap weighting as the primary approach. RESULTS: Among 883 patients who completed the 1-mg DST, DST nonsuppression was observed in 12.2%. Its prevalence showed an increasing pattern across groups, being lowest in individuals without PA, intermediate in patients with PA without adrenal nodules, and highest in those with adrenal nodules. Adrenal nodules were independently associated with DST nonsuppression (odds ratio, 2.68 [95% CI, 1.01-7.12]), with consistent findings across propensity score-based analyses. Among patients with PA without adrenal nodules, DST nonsuppression was associated with lower estimated glomerular filtration rate and a higher prevalence of chronic kidney disease. CONCLUSIONS: In the high-risk population with PA, DST nonsuppression was not randomly distributed across predefined groups and was independently associated with adrenal nodules. Even in the absence of adrenal nodules, DST nonsuppression was associated by less favorable renal markers, supporting its consistent association with clinical characteristics in patients with PA, rather than implying a distinct biochemical characteristic.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) conducted an observational in Hypertension suspected of primary aldosteronism (n=883). Adrenal nodules vs. Absence of adrenal nodules was evaluated on Dexamethasone suppression test (DST) nonsuppression (OR 2.68, 95% CI 1.01-7.12). In patients evaluated for primary aldosteronism, the presence of adrenal nodules was independently associated with dexamethasone nonsuppression (OR 2.68; 95% CI 1.01-7.12).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: